Stratification of patients with stage I NSCLC into low and high NPX-based “risk groups” by considering the median NPX value of CD244 at baseline as a cut-off, revealed significant differences between both “risk groups”. The gene discussed is CD244; the disease is non-small cell lung carcinoma.